Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+10.00%+5.18%+54.35%+71.20% 60.57B
+1.44%+4.06%+22.70%+101.03% 55.51B
+3.32%+4.11%+14.82%+75.04% 55.22B
+0.46%-2.86%+23.34%+33.77% 43.27B
+6.42%+3.20%+21.14%+105.56% 40.36B
+2.82%+7.24%+236.59%+801.17% 41.63B
-3.79%+19.39%+91.90%+77.13% 33.29B
+5.32%+6.04%+20.27%+52.98% 32.27B
+5.32%+15.84%-40.93%+342.66% 22.91B
Average +3.72%+5.02%+49.35%+184.51% 42.78B
Weighted average by Cap. +3.72%+4.06%+51.58%+169.51%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock